Homoisoflavonoids as potential antiangiogenic agents for retinal neovascularization

Biomed Pharmacother. 2017 Nov:95:818-827. doi: 10.1016/j.biopha.2017.09.004. Epub 2017 Sep 10.

Abstract

A number of people worldwide have been suffering from ocular neovascularization that may be treated by a variety of drugs but these may possess adverse effects. Therefore, small antiangiogenic molecules with higher potency and lower toxic effects are intended. However, homoisoflavonoids of natural origin show the potential antiangiogenic effect in ocular neovascularization. These homoisoflavonoids are judged quantitatively in terms of statistical validation through multi-chemometric modeling approaches for the betterment and refinement of their structures required for higher antiangiogenic activity targeted to ocular neovascularization. These approaches may be utilized to design better antiangiogenic homoisoflavonoids.

Keywords: ANN; Bayesian model; FA-MLR; Homoisoflavonoid; LDA; Neovascularization; PCRA; S-MLR; SVM.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / chemistry
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Biological Products / therapeutic use
  • Humans
  • Isoflavones / therapeutic use*
  • Retinal Neovascularization / drug therapy*
  • Small Molecule Libraries / therapeutic use
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Biological Products
  • Isoflavones
  • Small Molecule Libraries
  • Vascular Endothelial Growth Factor A